Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
This month we are discussing the management of severe neurotrophic keratitis (NK), an uncommon but severe degenerative disease of the cornea characterized by compromised corneal sensory innervation. Oxervate (cenegermin-bkbj, Dompé), a recombinant human nerve growth factor for topical administration, has been a game changer in the treatment of patients with NK. It is FDA approved but requires a